S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Geron Stock Forecast, Price & News

+0.02 (+1.33%)
(As of 06/29/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
2.15 million shs
Average Volume
2.43 million shs
Market Capitalization
$573.72 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Stock Forecast (MarketRank)

Overall MarketRank

1.80 out of 5 stars

Medical Sector

809th out of 1,432 stocks

Pharmaceutical Preparations Industry

400th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
Geron logo

About Geron (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-116.11 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.39 million
Book Value
$0.39 per share


Free Float
Market Cap
$573.72 million

Geron Frequently Asked Questions

Should I buy or sell Geron stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron
or view top-rated stocks.

What is Geron's stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month target prices for Geron's stock. Their GERN stock forecasts range from $4.00 to $7.00. On average, they anticipate Geron's share price to reach $5.50 in the next year. This suggests a possible upside of 261.8% from the stock's current price.
View analysts' price targets for Geron
or view top-rated stocks among Wall Street analysts.

How has Geron's stock price performed in 2022?

Geron's stock was trading at $1.22 at the start of the year. Since then, GERN shares have increased by 24.6% and is now trading at $1.52.
View the best growth stocks for 2022 here

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Geron

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.10 million. Geron had a negative net margin of 8,584.92% and a negative trailing twelve-month return on equity of 85.84%. During the same quarter in the previous year, the firm earned ($0.09) EPS.
View Geron's earnings history

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett M.D., Chairman, Pres & CEO (Age 71, Pay $1.26M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 53, Pay $743.27k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 58, Pay $767.28k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Operations & Chief Alliance Officer (Age 58, Pay $753.22k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 47, Pay $866.73k)
  • Mr. Anil Kapur, Exec. VP of Corp. Strategy & Chief Commercial Officer (Age 52, Pay $654.89k)
  • Ms. Suzanne Messere, Head of Investor Relations & Corp. Communications
  • Mr. Stephen N. Rosenfield J.D., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 72)
  • Ms. Shannon Odam, VP of HR
  • Mr. Edward E. Koval, Exec. VP & Chief Bus. Officer (Age 60)

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

What other stocks do shareholders of Geron own?

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.52.

How much money does Geron make?

Geron (NASDAQ:GERN) has a market capitalization of $573.72 million and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116.11 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Geron have?

Geron employs 69 workers across the globe.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for Geron is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at [email protected], or via fax at 650-473-7750.

This page (NASDAQ:GERN) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.